We aim to identify the prevalence and management strategies of nine clinically important categories of antipsychotic adverse effects, namely: extrapyramidal symptoms; sedation; weight gain; type II diabetes; hyperprolactinaemia; metabolic syndrome, dyslipidaemia; sexual dysfunction; and cardiovascular effects.
Background:
Antipsychotic drugs are widely prescribed for schizophrenia and other mental disorders. The adverse effects of antipsychotics are common, with a potential negative impact on adherence and engagement. Despite this, the scientific study of the prevalence or management of adverse antipsychotic effects is a neglected area.
Method:
A systematic review was undertaken using pre-defined search criteria and three databases, with hand searching of citations and references. Inclusion was agreed on by two independent researchers after review of abstracts or full text. Quality analysis of included studies was conducted using pre-agreed criteria.
Results:
In total, 53 studies met inclusion criteria, revealing the following: (1) antipsychotic polypharmacy was associated with increased frequency of adverse effects, and (2) a longer duration of treatment is associated with greater severity (e.g. higher BMI); (3) clozapine was more strongly associated with metabolic disturbance than other antipsychotics in three studies and olanzapine was associated with the most weight gain in three studies; (4) hyperprolactinaemia was more common in women than men, but 50% men noted sexual dysfunction versus 25–50% in women; (5) despite clinical guideline recommendations there is a low rate of baseline testing for lipids and glucose; and (6) seven studies described adverse effect management strategies, but only two examined their efficacy – one found a significant reduction in weight with non-pharmacological group therapy and the other found a significant reduction in dyslipidaemia with statins.
Conclusions:
Antipsychotic adverse effects are diverse and frequently experienced, but are not often systematically assessed. There is a need for further scientific study concerning the management of these side effects.
AhmerSKhanRAIqbalSP (2008) Association between antipsychotics and weight gain among psychiatric outpatients in Pakistan: A retrospective cohort study. Ann Gen Psychiatry7: 12.
2.
AjetunmobiOTaylorMStocktonD. (2013) Early death in those previously hospitalised for mental healthcare in Scotland: A nationwide cohort study, 1986–2010. BMJ Open3: e002768.
3.
AttuxCMartiniLCAraújoCM. (2011) The effectiveness of a non-pharmacological intervention for weight gain management in severe mental disorders: Results from a national multicentric study. Rev Bras Psiquiatr33: 117–121.
4.
BaiYMChenTTYangWS. (2009) Association of adiponectin and metabolic syndrome among patients taking atypical antipsychotics for schizophrenia: A cohort study. Schizophr Res111: 1–8.
5.
BaiYMLinCCChenJY. (2011) Association of weight gain and metabolic syndrome in patients taking clozapine: An 8-year cohort study. J Clin Psychiatry72: 751–756.
6.
BantaJEMorratoEHLeeSW. (2009) Retrospective analysis of diabetes care in California Medicaid patients with mental illness. J Gen Intern Med24: 802–808.
7.
BarakYAizenbergD (2011) Switching to aripiprazole as a strategy for weight reduction: A meta-analysis in patients suffering from schizophrenia. J Obes2011: 898013.
8.
BarnesTREPatonC (2011) Antipsychotic polypharmacy in schizophrenia: Benefits and risks. CNS Drugs25: 383–399.
9.
BobesJGarc A-PortillaMPRejasJ. (2003) Frequency of sexual dysfunction and other reproductive side-effects in patients with schizophrenia treated with risperidone, olanzapine, quetiapine, or haloperidol: The results of the EIRE study. J Sex Marital Ther29: 125–147.
10.
BrooksJO3rdGoldbergJFKetterTA. (2011) Safety and tolerability associated with second-generation antipsychotic polytherapy in bipolar disorder: Findings from the Systematic Treatment Enhancement Program for Bipolar Disorder. J Clin Psychiatry72: 240–247.
11.
BusheCShawM (2007) Prevalence of hyperprolactinaemia in a naturalistic cohort of schizophrenia and bipolar outpatients during treatment with typical and atypical antipsychotics. J Psychopharmacol21: 768–773.
12.
BusheCYeomansDFloydT. (2008) Categorical prevalence and severity of hyperprolactinaemia in two UK cohorts of patients with severe mental illness during treatment with antipsychotics. J Psychopharmacol22(2 Suppl): 56–62.
13.
ByneWWhiteLParellaM. (1998) Tardive dyskinesia in a chronically institutionalized population of elderly schizophrenic patients: Prevalence and association with cognitive impairment. Int J Geriatr Psychiatry13: 473–479.
14.
ChagnonYCBureauAGendronD. (2007) Possible association of the pro-melanin-concentrating hormone gene with a greater body mass index as a side effect of the antipsychotic olanzapine. Am J Med Genet B Neuropsychiatr Genet144: 1063–1069.
15.
ChongSAMythilyRemingtonG (2003) Clinical characteristics and associated factors in antipsychotic-induced akathisia of Asian patients with schizophrenia. Schizophr Res59: 67–71.
16.
ConcatoJShahNHorwitzRI (2000) Randomized, controlled trials, observational studies, and the hierarchy of research designs. N Engl J Med342: 1887–1892.
17.
CurtisJHenryCWatkinsA. (2011) Metabolic abnormalities in an early psychosis service: A retrospective, naturalistic cross-sectional study. Early Interv Psychiatry5: 108–114.
18.
DoknicMMaricNPBritvicD. (2011) Bone remodeling, bone mass and weight gain in patients with stabilized schizophrenia in real-life conditions treated with long-acting injectable risperidone. Neuroendocrinology94: 246–254.
19.
FalissardBMauriMShawK. (2011) The METEOR study: Frequency of metabolic disorders in patients with schizophrenia. Focus on first and second generation and level of risk of antipsychotic drugs. Int Clin Psychopharmacol26: 291–302.
FernandezHHFriedmanJHLansangMC. (2004) Diabetes mellitus among parkinsonian patients treated chronically with clozapine. Parkinsonism Relat Disord10: 439–441.
22.
FleischhackerWWMeiseUGüntherV. (1994) Compliance with antipsychotic drug treatment: Influence of side effects. Acta Psychiatr Scand Suppl382: 11–15.
23.
FujiiAYasui-FurukoriNSugawaraN. (2010) Sexual dysfunction in Japanese patients with schizophrenia treated with antipsychotics. Prog Neuropsychopharmacol Biol Psychiatry34: 288–293.
24.
GautamSMeenaPS (2011) Drug-emergent metabolic syndrome in patients with schizophrenia receiving atypical (second-generation) antipsychotics. Indian J Psychiatry53: 128–133.
25.
HäggSLindblomYMjörndalT. (2006) High prevalence of the metabolic syndrome among a Swedish cohort of patients with schizophrenia. Int Clin Psychopharmacol21: 93–98.
26.
HanssensLDe HertMKalnickaD. (2007) Pharmacological treatment of severe dyslipidaemia in patients with schizophrenia. Int Clin Psychopharmacol22: 43–49.
27.
HauptDWRosenblattLCKimE. (2009) Prevalence and predictors of lipid and glucose monitoring in commercially insured patients treated with second-generation antipsychotic agents. Am J Psychiatry166: 345–353.
28.
HomelPCaseyDAllisonDB (2002) Changes in body mass index for individuals with and without schizophrenia, 1987–1996. Schizophr Res55: 277–284.
29.
IqbalSPKhanRAAhmerS (2011) Antipsychotic treatment and weight gain: Does risperidone behave differently in Pakistani psychiatric patients?J Ayub Med Coll Abbottabad23: 66–69.
30.
JerrellJMMcIntyreRS (2007) Cerebro- and cardiovascular conditions in adults with schizophrenia treated with antipsychotic medications. Hum Psychopharmacol22: 361–364.
31.
JerrellJMMcIntyreRS (2008) Adverse events in children and adolescents treated with antipsychotic medications. Hum Psychopharmacol23: 283–290.
32.
JerrellJMHwangTLLivingstonTS (2008) Neurological adverse events associated with antipsychotic treatment in children and adolescents. J Child Neurol23: 1392–1399.
33.
JerrellJMMcIntyreRSTripathiA (2010) Incidence and costs of cardiometabolic conditions in patients with schizophrenia treated with antipsychotic medications. Clin Schizophr Relat Psychoses4: 161–168.
34.
KellyDLMcMahonRPLiuF. (2010) Cardiovascular disease mortality in patients with chronic schizophrenia treated with clozapine: A retrospective cohort study. J Clin Psychiatry71: 304–311.
35.
KendallT (2011) The rise and fall of the atypical antipsychotics. Br J Psychiatry199: 266–268.
36.
KhannaPKomossaKRummel-KlugeC. (2013) Aripiprazole versus other atypical antipsychotics for schizophrenia. Cochrane Database Syst Rev2: CD006569.
37.
KhawajaMY (2005) Sexual dysfunction in male patients taking antipsychotics. J Ayub Med Coll Abbottabad17: 73–75.
38.
KhazaalYFrésardEZimmermannG. (2006) Eating and weight related cognitions in people with schizophrenia: A case control study. Clin Pract Epidemiol Ment Health2: 29.
39.
KobyleckiCJJakobsenKDHansenT. (2009) CYP2D6 genotype predicts antipsychotic side effects in schizophrenia inpatients: A retrospective matched case-control study. Neuropsychobiology59: 222–226.
40.
Krane-GartiserKBreumLGlümrrC. (2011) Prevalence of the metabolic syndrome in Danish psychiatric outpatients treated with antipsychotics. Nord J Psychiatry65: 345–352.
41.
LambertMConusPEideP. (2004) Impact of present and past antipsychotic side effects on attitude toward typical antipsychotic treatment and adherence. Eur Psychiatry19: 415–422.
42.
LaursenTMWahlbeckKHällgrenJ. ( 2013) Life expectancy and death by diseases of the circulatory system in patients with bipolar disorder or schizophrenia in the Nordic countries. PLoS One8: e67133.
43.
Le NouryJKhanAHarrisM. (2008) The incidence and prevalence of diabetes in patients with serious mental illness in North West Wales: Two cohorts, 1875–1924 & 1994–2006 compared. BMC Psychiatry8: 67.
44.
LenczTMalhotraAK (2009) Pharmacogenetics of antipsychotic-induced side effects. Dialogues Clin Neurosci11: 405–415.
45.
LeuchtSArbterDEngelRR. (2009a) How effective are second-generation antipsychotic drugs? A meta-analysis of placebo-controlled trials. Mol Psychiatry14: 429–447.
46.
LeuchtSCiprianiASpineliL. (2013) Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: A multiple-treatments meta-analysis. Lancet382: 951–962.
47.
LeuchtSCorvesCArbterD. (2009b) Second-generation versus first-generation antipsychotic drugs for schizophrenia: A meta-analysis. Lancet373: 31–41.
48.
LeuchtSTardyMKomossaK. (2012) Antipsychotic drugs versus placebo for relapse prevention in schizophrenia: A systematic review and meta-analysis. Lancet379: 2063–2071.
49.
LeungSKUngvariGSNgFS. (2003) Tardive dyskinesia in Chinese inpatients with chronic schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry27: 1029–1035.
50.
LewisR (1998) Typical and atypical antipsychotics in adolescent schizophrenia: Efficacy, tolerability, and differential sensitivity to extrapyramidal symptoms. Can J Psychiatry43: 596–604.
51.
MacFarlaneIAGillGVFinneganD. (2004) Diabetes in a high secure hospital. Postgrad Med J80: 35–37.
52.
MackinPYoungAH (2005) QTc interval measurement and metabolic parameters in psychiatric patients taking typical or atypical antipsychotic drugs: A preliminary study. J Clin Psychiatry66: 1386–1391.
53.
MackinPBishopDRWatkinsonHM. (2007a) A prospective study of monitoring practices for metabolic disease in antipsychotic-treated community psychiatric patients. BMC Psychiatry7: 28.
54.
MackinPBishopDWatkinsonH. (2007b) Metabolic disease and cardiovascular risk in people treated with antipsychotics in the community. Br J Psychiatry191: 23–29.
55.
McCannTVClarkELuS (2009) Subjective side effects of antipsychotics and medication adherence in people with schizophrenia. J Adv Nurs65: 534–543.
56.
McIntyreRSJerrellJM (2008) Metabolic and cardiovascular adverse events associated with antipsychotic treatment in children and adolescents. Arch Pediatr Adolesc Med162: 929–935.
57.
MorratoEHNewcomerJWAllenRR. (2008) Prevalence of baseline serum glucose and lipid testing in users of second-generation antipsychotic drugs: A retrospective, population-based study of Medicaid claims data. J Clin Psychiatry69: 316–322.
58.
MukherjeeSDecinaPBocolaV. (1996) Diabetes mellitus in schizophrenic patients. Compr Psychiatry37: 68–73.
59.
MuzykAJRayfieldARevolloJY. (2012) Examination of baseline risk factors for QTc interval prolongation in patients prescribed intravenous haloperidol. Drug Saf35: 547–553.
60.
OkumuraYItoHKobayashiM. (2010) Prevalence of diabetes and antipsychotic prescription patterns in patients with schizophrenia: A nationwide retrospective cohort study. Schizophr Res119: 145–152.
61.
PallavaAChaddaRKSoodM. (2012) Metabolic syndrome in schizophrenia: A comparative study of antipsychotic-free/naïve and antipsychotic-treated patients from India. Nord J Psychiatry66: 215–221.
62.
PatelNCHariparsadMMatias-AktharM. (2007) Body mass indexes and lipid profiles in hospitalized children and adolescents exposed to atypical antipsychotics. J Child Adolesc Psychopharmacol17: 303–311.
63.
PhilippeAVaivaGCasadebaigF (2005) Data on diabetes from the French cohort study in schizophrenia. Eur Psychiatry20(Suppl 4): S340–S344.
64.
ReistCMintzJAlbersLJ. (2007) Second-generation antipsychotic exposure and metabolic-related disorders in patients with schizophrenia: An observational pharmacoepidemiology study from 1988 to 2002. J Clin Psychopharmacol27: 46–51.
65.
Royal College of Psychiatrists (2012) National Audit of Schizophrenia. Report of the National Audit of Schizophrenia 2012. Royal College of Psychiatrists.
66.
Rummel-KlugeCKomossaKSchwarzS. (2010) Head-to-head comparisons of metabolic side effects of second generation antipsychotics in the treatment of schizophrenia: A systematic review and meta-analysis. Schizophr Res123: 225–233.
67.
SaariKKoponenHLaitinenJ. (2004) Hyperlipidemia in persons using antipsychotic medication: A general population-based birth cohort study. J Clin Psychiatry65: 547–550.
68.
SchorrSGSlooffCJBruggemanR. (2009) The incidence of metabolic syndrome and its reversal in a cohort of schizophrenic patients followed for one year. J Psychiatr Res43: 1106–1111.
69.
SIGN 131 (2013) Management of schizophrenia. Available at: www.sign.ac.uk.
70.
SmithDJLanganJMcLeanG. (2013) Schizophrenia is associated with excess multiple physical-health comorbidities but low levels of recorded cardiovascular disease in primary care: Cross-sectional study. BMJ Open3: e002808.
TaylorMShajahanPLawrieS (2008) Comparing the use and discontinuation of antipsychotics in clinical practice – an observational study. J Clin Psychiatry69: 240–245.
TsanJYStockEMGonzalezJM. (2012) Mortality and guideline-concordant care for older patients with schizophrenia: A retrospective longitudinal study. BMC Med10: 147.
75.
van HartenPNHoekHWMatroosGE. (2006) Incidence of tardive dyskinesia and tardive dystonia in African Caribbean patients on long-term antipsychotic treatment: The Curaçao extrapyramidal syndromes study V. J Clin Psychiatry67: 1920–1927.
76.
WaddellLTaylorM (2008) A new self-rating scale for detecting atypical or second-generation antipsychotic side effects. J Psychopharmacol22: 238–243.
77.
WhitakerARaoU (1992) Neuroleptics in pediatric psychiatry. Psychiatr Clin North Am15: 24376.
78.
WoodsSWMorgensternHSaksaJR. (2010) Incidence of tardive dyskinesia with atypical versus conventional antipsychotic medications: A prospective cohort study. J Clin Psychiatry71: 463–474.
79.
ZhangJPMalhotraAK (2011) Pharmacogenetics and antipsychotics: Therapeutic efficacy and side effects prediction. Expert Opin Drug Metab Toxicol7: 9–37.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
